Citius Oncology Engages CTCL Experts at USCLC Workshop to Boost LYMPHIR Adoption
Event summary
- Citius Oncology to participate in USCLC Annual Workshop 2026 on March 26, 2026, to discuss LYMPHIR™ with CTCL specialists.
- LYMPHIR™, launched in December 2025, targets relapsed/refractory Stage I-III CTCL after prior systemic therapy.
- USCLC Workshop convenes key opinion leaders and clinical investigators from major U.S. cancer centers.
- Citius Oncology estimates the initial market for LYMPHIR™ exceeds $400 million and is growing.
The big picture
Citius Oncology's participation in the USCLC Annual Workshop underscores its strategic focus on engaging with leading CTCL experts to drive LYMPHIR™ adoption. The workshop provides a platform for direct interaction with key opinion leaders, facilitating discussions on treatment paradigms and clinical experience. With an estimated market exceeding $400 million, Citius Oncology aims to position LYMPHIR™ as a competitive therapy in the underserved CTCL space.
What we're watching
- Market Penetration
- How Citius Oncology will leverage USCLC Workshop to accelerate LYMPHIR™ adoption among CTCL specialists.
- Competitive Positioning
- Whether Citius Oncology can sustain LYMPHIR™'s market share against existing therapies in the growing CTCL market.
- Regulatory Compliance
- The pace at which Citius Oncology addresses post-marketing requirements and ongoing regulatory compliance for LYMPHIR™.
Related topics